Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Pharmacol ; 59(8): 1078-1084, 2019 08.
Article in English | MEDLINE | ID: mdl-30861160

ABSTRACT

For more than a decade, first responders and the general public have been able to treat suspected opioid overdoses using an improvised nasal naloxone device (INND) constructed from a prefilled syringe containing 2 mg of naloxone (1 mg/mL) attached to a mucosal atomization device. In recent years, the U.S. Food and Drug Administration (FDA)-approved Ezvio, an autoinjector that delivers 2 mg by intramuscular injection and Narcan nasal spray (2- and 4-mg strengths; 0.1 mL/dose) for the emergency treatment of a known or suspected opioid overdose. The present study was conducted to compare the pharmacokinetics of naloxone using the FDA-approved devices (each administered once) and either 1 or 2 administrations using the INND. When naloxone was administered twice using the improvised device, the doses were separated by 2 minutes. The highest maximum plasma concentration was achieved using the 4-mg FDA-approved spray. The highest exposures at 5 minutes postdose, based on AUC values, were after administration with the autoinjector and the 4-mg FDA-approved spray; at 10, 15, and 20 minutes postdose, the latter yielded the greatest exposure. Even after 2 administrations, the INND failed to achieve naloxone plasma levels comparable to the FDA-approved devices at any time. The ease of use and higher plasma concentrations achieved using the 4-mg FDA-approved spray, compared with the INND, should be considered when deciding which naloxone device to use.


Subject(s)
Naloxone/administration & dosage , Naloxone/pharmacokinetics , Narcotic Antagonists/administration & dosage , Narcotic Antagonists/pharmacokinetics , Administration, Intranasal , Adult , Cross-Over Studies , Drug Approval , Female , Humans , Injections, Intramuscular , Male , Middle Aged , Naloxone/adverse effects , Naloxone/blood , Narcotic Antagonists/adverse effects , Narcotic Antagonists/blood , United States , United States Food and Drug Administration , Young Adult
2.
Alcohol Clin Exp Res ; 36(5): 863-73, 2012 May.
Article in English | MEDLINE | ID: mdl-22150508

ABSTRACT

BACKGROUND: Concurrent inhibitors of dopamine, norepinephrine, and serotonin uptake have been proposed as novel antidepressants. Given the high comorbidity between alcoholism and depression, we evaluated the activity of DOV 102,677 (DOV) on alcohol-maintained responding and performance in the forced swim test (FST), a model of antidepressant (AD) activity, using alcohol-preferring (P) rats. METHODS: Following training to lever press for either alcohol (10% v/v) or sucrose (3, 2%, w/v) on a fixed-ratio 4 (FR4) schedule, DOV (1.56 to 50 mg/kg; PO) was given 25 minutes or 24 hours prior to evaluation. The effects of DOV (12.5 to 50 mg/kg; PO) in the FST were evaluated 25 minutes posttreatment. RESULTS: DOV (6.25 to 50 mg/kg) dose-dependently reduced alcohol-maintained responding by 59 to 88% at 25 minutes posttreatment, without significantly altering sucrose responding. The reduction in alcohol responding (44% at 50 mg/kg) was sustained for up to 120 hours after a single dose. Administration of a single dose of DOV (25, 50 mg/kg) 24 hours before testing suppressed alcohol responding for 48 hours by 59 to 62%. DOV (12.5 to 50 mg/kg) also dose-dependently reduced immobility of P rats in the FST. CONCLUSIONS: DOV produces both prolonged and selective reductions of alcohol-motivated behaviors in P rats. The elimination kinetics of DOV suggests that its long duration of action may be due to an active metabolite. DOV also produced robust AD-like effects in P rats. We propose that DOV may be useful in treating comorbid alcoholism and depression in humans.


Subject(s)
Alcoholism/complications , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Depression/drug therapy , Neurotransmitter Uptake Inhibitors/therapeutic use , Alcoholism/drug therapy , Animals , Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics , Central Nervous System Depressants/administration & dosage , Depression/complications , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Ethanol/administration & dosage , Male , Neurotransmitter Uptake Inhibitors/pharmacokinetics , Rats , Rats, Sprague-Dawley , Sucrose/administration & dosage , Sweetening Agents/administration & dosage , Swimming
3.
J Pharmacol Exp Ther ; 324(3): 1111-26, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18089843

ABSTRACT

Selective inhibitors of biogenic amine (e.g., serotonin, norepinephrine, and dopamine) uptake exhibit varying degrees of safety and efficacy as antiobesity agents. Moreover, preclinical findings suggest that the combined inhibition of monoamine neurotransmitter transporters synergistically enhances antiobesity activity. (1R,5S)-(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo-[3.1.0] hexane hydrochloride (DOV 21947) inhibits norepinephrine, 5-hydroxytryptamine, and dopamine uptake, and it reduces body weight in rodent models of diet-induced obesity (DIO). DIO rats treated orally with DOV 21947 for 1 to 24 days showed significantly lower body weights than vehicle-treated DIO rats. The decrease in body weight resulted specifically from a loss of retroperitoneal and mesenteric depots of white adipose tissue. DOV 21947 also reduced daily food intake in DIO rats, but consumption returned to control levels after 11 days of treatment. With the exception of a decrease in triglyceride levels, blood chemistry was unaltered after 24 days of DOV 21947 treatments. DOV 21947 had no effect on motor activity. Although DOV 21947 increased respiratory rate and decreased the tidal volume of normal rats, it did not alter the minute volume. In addition, DOV 21947 did not significantly affect blood pressure, heart rate, electrocardiographic indices or body temperature in telemeterized dogs. However, it caused a sustained, but reversible reduction in the rate of body weight gain for as long as 6 months in normal rats, and for up to 1 year in normal dogs. In summary, DOV 21947 is effective in causing a sustained and selective reduction in fat content and triglyceride levels in animal models of obesity without significantly altering vital organ function.


Subject(s)
Aza Compounds/therapeutic use , Body Weight/drug effects , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Dietary Fats/blood , Disease Models, Animal , Obesity/drug therapy , Triglycerides/blood , Animals , Anti-Obesity Agents/pharmacology , Anti-Obesity Agents/therapeutic use , Aza Compounds/pharmacology , Body Weight/physiology , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Cardiovascular System/drug effects , Dietary Fats/adverse effects , Dogs , Dose-Response Relationship, Drug , Female , Male , Mice , Mice, Inbred C57BL , Neurotransmitter Uptake Inhibitors/pharmacology , Neurotransmitter Uptake Inhibitors/therapeutic use , Obesity/blood , Rats , Rats, Sprague-Dawley , Weight Gain/drug effects , Weight Gain/physiology
4.
Drug Metab Dispos ; 36(2): 241-51, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17991767

ABSTRACT

Bicifadine [DOV 220,075; (+/-)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]-hexane HCl)] is a non-narcotic analgesic that is effective in animal models of acute and chronic pain. In this study, the pharmacokinetics, disposition, and metabolism of bicifadine were determined in male and female mice, rats, and cynomolgus monkeys following single oral and i.v. doses. [(14)C]Bicifadine was well absorbed in all three species. The oral bioavailability of bicifadine in mice and rats was 50 to 63% and 79 to 85%, respectively, and slightly lower in monkeys (33-42%). Based on the values of the area under the concentration-time curves, unchanged bicifadine comprised 7 to 12% of the plasma radioactivity after the oral dose and 14 to 26% after the i.v. dose in all three species. The major plasma metabolites were the lactam (M12), the lactam acid (M9), and the acid (M3) plus its glucuronide conjugate. At 0.5 h after the oral dose to rats, 63 to 64% of the radioactivity in the rat brain was bicifadine, and the remainder was the lactam. Most of the radioactivity after oral and i.v. dosing to the three species was recovered in the urine. The lactam acid was the major urinary metabolite in all species; bicifadine and the lactam were either not detected or were minor components in urine. Fecal radioactivity was due to the acid and lactam acid in the three species. Rat bile contained mainly the lactam acid and the acid plus its acyl glucuronide. Plasma protein binding of [(14)C]bicifadine was moderate in the mouse (80-86%) and higher in the rat and monkey (95-97%). In summary, bicifadine was well absorbed, extensively metabolized, and excreted via the urine and feces as metabolites.


Subject(s)
Analgesics/pharmacokinetics , Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics , Administration, Oral , Analgesics/administration & dosage , Analgesics/blood , Analgesics/urine , Animals , Bile/chemistry , Blood Proteins/metabolism , Brain/metabolism , Bridged Bicyclo Compounds, Heterocyclic/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic/blood , Bridged Bicyclo Compounds, Heterocyclic/urine , Feces/chemistry , Female , Injections, Intravenous , Macaca fascicularis , Male , Mice , Mice, Inbred Strains , Rats , Rats, Sprague-Dawley
5.
Drug Metab Dispos ; 36(2): 252-9, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17991768

ABSTRACT

Bicifadine [DOV 220,075; (+/-)-1-(4-methylphenyl)-3-azabicyclo-[3.1.0]hexane HCl)] is a non-narcotic analgesic that has proven to be effective for the treatment of acute pain in clinical studies. The pharmacokinetics, disposition, and metabolism of bicifadine were determined in eight healthy adult male subjects following a single oral dose of 200 mg of [(14)C]bicifadine in solution. The maximum concentration of total drug equivalents and bicifadine in plasma was at approximately 1 h; the elimination half-life was 2.6 and 1.6 h for radioactivity and bicifadine, respectively. Unchanged bicifadine represented 15% of the area under the concentration-time curve for total drug equivalents; the rest was due mainly to the lactam (M12), the acid (M3), and the lactam acid (M9). Total recovery of the dose was 92%, with most of the radioactivity recovered in the urine in the first 24 h; fecal excretion accounted for only 3.5% of the dose. Approximately 64% of the dose was metabolized to M9 and its acyl glucuronide; another 23% was recovered as M3 and its acyl glucuronide. Neither bicifadine nor M12 were detected in urine or feces. There were no reported serious or severe adverse events during the study.


Subject(s)
Analgesics/pharmacokinetics , Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics , Adult , Analgesics/blood , Analgesics/urine , Bridged Bicyclo Compounds, Heterocyclic/blood , Bridged Bicyclo Compounds, Heterocyclic/urine , Feces/chemistry , Humans , Male
6.
Drug Metab Dispos ; 35(12): 2232-41, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17881661

ABSTRACT

The in vitro metabolism of [(14)C]bicifadine by hepatic microsomes and hepatocytes from mouse, rat, monkey, and human was compared using radiometric high-performance liquid chromatography and liquid chromatography/tandem mass spectrometry. Two main metabolic pathways were identified in all four species. One pathway was an NADPH-dependent pathway in which the methyl group was oxidized to form a hydroxymethyl metabolite (M2). Its formation was inhibited in human microsomes only by quinidine, a CYP2D6 inhibitor. In incubations with individual cDNA-expressed human cytochromes P450, M2 was formed only by CYP2D6 and CYP1A2, with CYP2D6 activity 6-fold greater than that of CYP1A2. M2 was oxidized further to the carboxylic acid metabolite (M3) by hepatocytes from all four species. The second major metabolic pathway was an NADPH-independent oxidation at the C2 position of the pyrrolidine ring, forming a lactam metabolite (M12). This reaction was almost completely inhibited in human hepatic microsomes and mitochondria by the monoamine oxidase (MAO)-B-specific inhibitor selegiline. Clorgyline, a specific inhibitor of MAO-A, was less effective in inhibiting M12 formation. Other metabolic pathways of variable significance among the four species included the formation of carbamoyl-O-glucuronide, hydroxymethyl lactam, and carboxyl lactam. Overall, the data indicate that the primary enzymes responsible for the primary metabolism of bicifadine in humans are MAO-B and CYP2D6.


Subject(s)
Analgesics/metabolism , Bridged Bicyclo Compounds, Heterocyclic/metabolism , Cytochrome P-450 CYP1A2/metabolism , Cytochrome P-450 CYP2D6/metabolism , Liver/enzymology , Monoamine Oxidase/metabolism , Animals , Carbon Radioisotopes , Carboxylic Acids/metabolism , Chromatography, High Pressure Liquid , Clorgyline/pharmacology , Cytochrome P-450 CYP2D6 Inhibitors , Enzyme Inhibitors/pharmacology , Female , Glucuronides/metabolism , Hepatocytes/enzymology , Humans , Hydroxylation , In Vitro Techniques , Lactams/metabolism , Liver/cytology , Liver/drug effects , Macaca fascicularis , Male , Mice , Microsomes, Liver/enzymology , Middle Aged , Mitochondria, Liver/enzymology , Monoamine Oxidase Inhibitors/pharmacology , NADP/metabolism , Oxidation-Reduction , Quinidine/pharmacology , Rats , Rats, Sprague-Dawley , Recombinant Proteins/metabolism , Selegiline/pharmacology , Species Specificity , Tandem Mass Spectrometry
7.
J Pharmacol Exp Ther ; 321(3): 1208-25, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17325229

ABSTRACT

Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) inhibits monoamine neurotransmitter uptake by recombinant human transporters in vitro with a relative potency of norepinephrine > serotonin > dopamine (approximately 1:2:17). This in vitro profile is supported by microdialysis studies in freely moving rats, where bicifadine (20 mg/kg i.p.) increased extrasynaptic norepinephrine and serotonin levels in the prefrontal cortex, norepinephrine levels in the locus coeruleus, and dopamine levels in the striatum. Orally administered bicifadine is an effective antinociceptive in several models of acute, persistent, and chronic pain. Bicifadine potently suppressed pain responses in both the Randall-Selitto and kaolin models of acute inflammatory pain and in the phenyl-p-quinone-induced and colonic distension models of persistent visceral pain. Unlike many transport inhibitors, bicifadine was potent and completely efficacious in both phases of the formalin test in both rats and mice. Bicifadine also normalized the nociceptive threshold in the complete Freund's adjuvant model of persistent inflammatory pain and suppressed mechanical and thermal hyperalgesia and mechanical allodynia in the spinal nerve ligation model of chronic neuropathic pain. Mechanical hyperalgesia was also reduced by bicifadine in the streptozotocin model of neuropathic pain. Administration of the D(2) receptor antagonist (-)-sulpiride reduced the effects of bicifadine in the mechanical hyperalgesia assessment in rats with spinal nerve ligations. These results indicate that bicifadine is a functional triple reuptake inhibitor with antinociceptive and antiallodynic activity in acute, persistent, and chronic pain models, with activation of dopaminergic pathways contributing to its antihyperalgesic actions.


Subject(s)
Analgesics/pharmacology , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Pain/drug therapy , Acute Disease , Analgesics/metabolism , Animals , Brain/drug effects , Brain/metabolism , Bridged Bicyclo Compounds, Heterocyclic/metabolism , Chronic Disease , Desipramine/pharmacology , Disease Models, Animal , Dopamine/metabolism , Dose-Response Relationship, Drug , Humans , Male , Mice , Microdialysis , Motor Activity/drug effects , Neurotransmitter Transport Proteins/antagonists & inhibitors , Neurotransmitter Transport Proteins/metabolism , Norepinephrine/metabolism , Pain/metabolism , Pain/physiopathology , Pain Threshold/drug effects , Rats , Rats, Sprague-Dawley , Rats, Wistar , Reaction Time/drug effects , Receptors, Neurotransmitter/antagonists & inhibitors , Receptors, Neurotransmitter/metabolism , Serotonin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...